Eczema Society of Canada launches annual lighting campaign to shine a spotlight on eczema this November TORONTO, Oct. 31, 2025 /CNW/ - November is Eczema ...
From relentless itching and painful flare-ups to sleepless nights and emotional exhaustion, eczema can take a serious toll on ...
More than 31 million people in the U.S. live with eczema, a chronic skin condition that can disrupt daily life yet continues ...
MG-K10 (generic name: Comekibart Injection) is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 ...
When most people think of eczema, they picture a dry, red, inflamed and itchy rash. But on darker skin tones, eczema can look ...
Experts discuss the impact of severe eczema on children’s daily lives and the role of newer non-steroidal topical therapies ...
Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory ...
Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 2B clinical study titled ‘A PHASE 2B, ...
Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Study Overview: Pfizer Inc. is conducting a clinical study titled ‘A ...
Despite being a first-line treatment for CHE, nearly 40% of patients treated with TCS had inadequate treatment response or contraindications to TCS.
Nearly 1 in 10 U.S. adults report having physician-diagnosed chronic head eczema, according to findings from a ...
Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback